Pierre Fabre Group
Edit

Pierre Fabre Group

https://www.pierre-fabre.com/
Last activity: 30.08.2024
Active
Categories: BusinessCareContent DistributionDrugEmployeeHealthTechManufacturingMarketMedtechProduct
Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : 💊 A pharmaceutical group with a strong positioning : medical and natural 🥈 The second largest dermo-cosmetics laboratory in the world 🥈 The second largest private French pharmaceutical group 🥇 The market leader in France for products sold over the counter in pharmacies. Our portfolio includes several medical franchises and international brands including ; Pharmaceutical Care Pierre Fabre Oncologie Pierre Fabre Dermatologie Naturactive Eau Thermale Avène Klorane Ducray René Furterer A-Derma Pierre Fabre Oral Care Glayton (US) Darrow (Brasil) Established in the Occitanie region since its creation, we manufacture over 95% of our products in France. We keep innovating passionately with our teams in 2 innovation centers in Brasil and Japan as well as in 6 R&D centers in France. Thanks to our 10,000 employees in 44 subsidiaries and our distribution activities in 130 countries, our group generated €2.3 billion in revenues in 2020, 65% of which is from international business. Pierre Fabre Group has a unique company structure. 86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan. This year, the independent organization ECOCERT Environment awarded Pierre Fabre's CSR policy at "excellence" level : - Excellence being the highest maturity level of the ECOCERT 26000 standard.
Followers
6.72K
Followers
322.28K
Website visits
209.7K /mo.
Mentions
33
Location: France, Occitania, Toulouse
Employees: 10001+
Founded date: 1962

Mentions in press and media 33

DateTitleDescription
30.08.2024Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell l...European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% i...
09.08.2024Eau Thermale Avène Launches Board-Certified Dermatologist Ulta Beauty SpokespersonPARSIPPANY, N.J., Aug. 9, 2024 /PRNewswire/ -- Eau Thermale Avène, a leader in dermo-cosmetics with over 275 years of expertise rooted in dermatology and hydrotherapy, announced its partnership at Ulta Beauty with board-certified dermatolog...
26.07.2024Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung ca...The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent...
28.06.2024Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.CASTRES, France, June 28, 2024 /PRNewswire/ -- The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particula...
23.06.2024Pierre Fabre Laboratories Wins Prestigious Galien International Prize for EBVALLO®Pierre Fabre Laboratories has been honored with the prestigious "Prix Galien International" Prize for their groundbreaking immunotherapy, EBVALLO®. This innovative treatment offers hope to patients with a rare cancer, post-transpl...
21.06.2024Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancerCASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indic...
21.06.2024Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancerCASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indic...
05.06.2024Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET AlterationsCASTRES, France, June 5, 2024 /PRNewswire/ -- Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-i...
05.06.2024Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET AlterationsCASTRES, France, June 5, 2024 /PRNewswire/ -- Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-i...
20.05.2024Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymph...First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration The BLA is supported by data from the pivotal Phase 3 ALLELE study which was investigating Tab-cel in relapsed or refractory EBV+ PTLD following solid organ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In